REG - Wellnex Life Limited - Issue of Equity - Pain Away vendor shares

Wellnex LifeAnnouncement

25/03/2025 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250325:nRSY0721Ca&default-theme=true

RNS Number : 0721C  Wellnex Life Limited  25 March 2025

25 March 2025

 

Wellnex Life Limited

("Wellnex Life" or the "Company")

 

Issue of Equity - Pain Away vendor shares

 

Wellnex Life Limited (AIM: WNX | ASX: WNX), an innovative brand and
distribution company focused on consumer health and wellness products,
announces that application has been made for the admission to trading on AIM
of 403,226 new ordinary shares of no par value ("Ordinary Shares") which have
been issued in connection with the settlement of the deferred consideration
which has been settled with the Pain Away vendors. The new Ordinary Shares
will rank pari passu in all respects with the Company's issued Ordinary Shares
and dealings are expected to commence on or around 26 March 2025.

 

Following Admission, the Company's issued share capital will comprise of
66,637,159 Ordinary Shares, none of which are held in treasury. Accordingly,
the figure of 66,637,159 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules and the
provisions of the Company's constitution.

 

 

Enquiries:

 

 Wellnex Life Limited                                                 https://wellnexlife.com.au (https://wellnexlife.com.au)
                                                                      via Walbrook PR

 Strand Hanson Limited (Financial & Nominated Advisor)                Tel: +44 (0)20 7409 3494

 James Harris / Richard Johnson / Robert Collins

 Orana Corporate LLP (Joint Broker)
 Sebastian Wykeham

 SP Angel Corporate Finance LLP (Joint Broker)                        Tel: +44 (0)20 3470 0470
 David Hignell

 Walbrook PR (UK Media & Investor Relations)                          Tel: +44 (0)20 7933 8780 or lifesciences@walbrookpr.com
                                                                      (mailto:lifesciences@walbrookpr.com)
 Paul McManus / Alice Woodings                                        Mob: +44 (0)7980 541 893/+44 (0)7407 804 654

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEPKPBBKBKDBNB